Actualizado 22/08/2008 10:02
- Comunicado -

Cymbalta Receives European Approval for the Treatment of Generalised Anxiety Disorder (y 2)

1 Koponen, H., et al. Efficacy of Duloxetine for the Treatment of Generalized Anxiety Disorder: Implications for Primary Care Physicians. Prim Care Companion J Clin Psychiatry 2007: 9(2):100-107

2 Rynn M., et al. Efficacy and Safety of Duloxetine in the Treatment of Generalized Anxiety Disorder: A Flexible-Dose, Progressive-Titration, Placebo-Controlled Trial. Depression and Anxiety 2007: 25(3): 182-189.

3 Hartford, J., et al. Duloxetine as an SNRI Treatment for Generalized Anxiety Disorder: Results from a Placebo- and Active-Controlled Trial. Int Clin Psychopharmacol 2007: 22(3):167-74.

4 Nicolini H, et al. Improvement of psychic and somatic symptoms in adult patients with generalized anxiety disorder: Examination from a duloxetine, venlafaxine extended-release, and placebo-controlled study. In Press at Psychological Medicine.

5 Endicott, J., et al. Duloxetine Treatment for Role Functioning Improvement in Generalized Anxiety Disorder: Three Independent Studies. The Journal of Clinical Psychiatry 2007: 68(4):518-24

6 Allgulander, C., et al. Pharmacotherapy of Generalized Anxiety Disorder: Results of Duloxetine Treatment from a Pooled Analysis of 3 Clinical Trials. Current Medical Research and Opinion 2007: 23(6): 1245-1252

7 Davidson JRT, et al. Duloxetine treatment for relapse prevention in adults with generalized anxiety disorder: A 26-week randomized placebo-controlled study. Poster presented at the American College of Neuropsychopharmacology annual conference 2007. Boca Raton, Florida

8 Lieb, R, et al. The epidemiology of generalised anxiety disorder in Europe. European Neuropsychopharmacology 2005 Aug;15(4):445-52.

9 National Institute of Economic and Social Research. Summarized from the National Institute Economic Review,194, 28 October 2005.

10 Calculated extrapolations of prevalence rates against the populations of a particular country or region, based upon prevalence of generalized anxiety disorder in the US, UK, Canada or Australia. Available at: http://www.cureresearch.com/g/generalize... . Accessed on 2.4.08

11 National Institute of Mental Health (NIMH). Anxiety Disorders. Available at: http://www.nimh.nih.gov/health/publications/anxiety-disorder... -anxiety-disorder-gad.shtml . Accessed on 2.5.08

12 Bymaster, FP et al. The Dual Transporter Inhibitor Duloxetine: A Review of its Preclinical Pharmacology, Pharmacokinetic Profile, and Clinical Results in Depression. Current Pharmaceutical Design. 2005; 11: 1475-1493.

13 Patient.co.uk. Generalized anxiety disorder. Available at http://www.patient.co.uk/showdoc/2700012... . Accessed on 2.5.08

    
    (Logo: http://www.newscom.com/cgi-bin/prnh/20031219/LLYLOGO )
    (Logo: http://www.newscom.com/cgi-bin/prnh/20070319/NYM004LOGO )

Charles McAtee, Eli Lilly and Company, +1-317-277-1566; or Eva Freitag, Boehringer Ingelheim, +49(6132)77-2964 ; Photo: http://www.newscom.com/cgi-bin/prnh/20031219/LLYLOGO, http://www.newscom.com/cgi-bin/prnh/20070319/NYM004LOGO, PRN Photo Desk, photodesk@prnewswire.com

Comunicados

Si quieres mejorar el posicionamiento online de tu marca, ahora puedes publicar tus notas de prensa o comunicados de empresa en la sección de Comunicados de europa press

Si necesitas asesoramiento en comunicación, redacción de tus notas de prensa o ampliar la difusión de tu comunicado más allá de la página web de europa press, ponte en contacto con nosotros en comunicacion@europapress.es o en el teléfono 913592600